Nasal Spray Could Delay Alzheimer's by Years
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...
'We are very hopeful' | New nasal spray could delay Alzheimer's by years, researchers say
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Scientists Develop Breakthrough Nasal Spray That Could Delay Alzheimer’s by Over a Decade
Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...
CNET on MSN4d
Which Decongestants Are Effective? Why the FDA Wants to Pull a Popular Medicine Ingredient
Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...
FDA seeks to remove ingredient from cold medicines after data shows it does not work
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
Health on MSN6d
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...
WSB-TV6d
FDA proposes pulling oral phenylephrine, found in many decongestants, from shelves
but without a prescription. Pseudoephedrine in large quantities can be used to make methamphetamine. Last September, an FDA ...
JD Supra6d
FDA Approves the First Flu Vaccine for At Home Use, Providing a Needle Free Option Outside of Traditional Health Care Settings
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...
Business Insider5d
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand ... medication and many also fail to renew their ...
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® (Nasdaq: MIST) today reported financial results for the ...
Neuroscience News7d
New Nasal Spray Could Delay Alzheimer’s Progression by Years
Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...
Pharmabiz2d
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions
The agreement grants ALK exclusive global rights to the neffy adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand ... medication and many also fail to renew their ...